LBA-003Phase 1b/II study of cancer stemness inhibitor napabucasin in combination with FOLFIRI +/- bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts).
暂无分享，去创建一个
A. Grothey | J. Bendell | H. Pitot | D. Jonker | T. Halfdanarson | B. Adesunloye | J. Edenfield | B. O'Neil | W. Li | A. Starodub | J. Hubbard | J. Zubkus | J. Peyton | Y. Li | B. Nadeau | L. Borodyansky | C. Li